June 8th, 2026
A small number of humans with an inherited PAI-1 loss of function mutation live up to seven years longer than peers. PAI-1 appears involved in cellular senescence, and thus effects on health and life span may reflect a lower burden of harm resulting from the presence of increasing numbers of senescent cells with advancing age. Researchers have been developing small molecule drugs to inhibit PAI-1 activity, and here find a review paper covering these efforts. Recall that inhibition via a small molecule drug tends to have a much smaller effect than a loss of function mutation, as firstly the drug is only used for part of a life span, and secondly the drug does not produce complete inhibition of activity. This is nonetheless how research and development tends to progress.
Plasminogen activator inhibitor-1 (PAI-1), encoded by SERPINE1, is the principal physiological inhibitor of tissue-type and urokinase-type plasminogen activators and a central regulator of fibrinolysis. Beyond its canonical hemostatic role, PAI-1 has emerged as a pleiotropic mediator of tissue remodeling, fibrosis, metabolic dysfunction, cancer progression, cellular senescence, and age-associated immune dysregulation. A central argument of this review is that PAI-1 should be understood not only as a downstream biomarker of aging-associated pathology, but also as an active effector linking senescence-associated secretory phenotype (SASP) signaling, chronic low-grade inflammation, impaired immune surveillance, fibrotic extracellular matrix remodeling, and a prothrombotic state.
